Oncternal Therapeutics Q2 2024 GAAP EPS $(2.89) Beats $(3.10) Estimate, Sales $801.000K Beat $237.500K Estimate
Portfolio Pulse from Benzinga Newsdesk
Oncternal Therapeutics (NASDAQ:ONCT) reported Q2 2024 GAAP EPS of $(2.89), beating the $(3.10) estimate. Sales were $801,000, significantly surpassing the $237,500 estimate and showing a 655.66% increase from the same period last year.
August 08, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oncternal Therapeutics reported better-than-expected Q2 2024 earnings and sales, with EPS of $(2.89) beating the $(3.10) estimate and sales of $801,000 surpassing the $237,500 estimate. This represents a significant 655.66% increase in sales compared to the same period last year.
The better-than-expected earnings and significant increase in sales are likely to positively impact Oncternal Therapeutics' stock price in the short term. Beating both EPS and sales estimates by a wide margin indicates strong performance and could boost investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100